Cell Procurement & Processing

电池采购

基本信息

  • 批准号:
    10595863
  • 负责人:
  • 金额:
    $ 7.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-08-01 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT - Cell Procurement and Processing Core The purpose and objective of the Cell Procurement and Processing (Cell P&P) Core remains to advance the understanding of hematopoiesis and nonmalignant disorders through the distribution of high-quality hematopoietic products to the hematology research community. To meet this need, the early precursors of Cell P&P Core was first established in 1999 under the original CCEH P30. Over the almost 20-year history, The Cell P&P Core has become recognized as a national resource for normal hematopoietic cell products, as evidenced by the 171 investigators at 69 institutions who have received hematopoietic products during the previous award period. Moreover, utilization of resources from the Core have continued to grow and facilitate investigations that have advanced our understanding of the biology governing normal hematopoiesis and nonmalignant disorders. As part of the proposed award, the Cell P&P Core will leverage its expertise, infrastructure, and experiences to increase production and utilization of the high-quality products to advance the field of hematology research, while maintaining the current high standards for product quality as detailed in the Research Strategy. Therefore, the Cell P&P Core proposes the following: Specific Aim 1. Expand the number of users for enriched hematopoietic cell products of the highest quality and uniformity to facilitate hematology research. We propose three new approaches to increase user numbers. 1) The Cell P&P Core develop a novel User Satisfaction and Needs Program to provide feedback and identify new users. 2) The Core will develop Virtual Workshops targeting existing and new users. 3) The Core will develop a novel funding mechanism called Cell P&P New Investigator Award that provide resources at significantly reduced prices. Specific Aim 2. Develop user-friendly, integrative and comprehensive Data Management System (DMS) for hematopoietic specimens. The proposed DMS will incorporate real-time assessment for tracking and retrieval of donor characteristic, pre-analytic variables, SOPs, inventory, quality controls, quality assurances, and specimen distribution, which will have two major beneficial effects. 1) The Core will be able to more efficiently provide users with the essential variables related to their research. 2) The Core will be able to more rapidly and comprehensively assess quality measures and evaluate potential variables impacting product uniformity. Specific Aim 3. Develop new and innovative user-directed products to facilitate hematology research. Given the explosion of new technologies to examine hematopoietic cells, it remains a challenge for investigators to acquire the skills to take advantage of these technologies. By combining the expertise of Cell P&P and Tool Cores, we will be able to efficiently develop and deliver user-directed products to those investigators who may not otherwise be able to develop these products within their labs. Through these deliverables, we will broaden the research potential for these investigators and provide a mechanism to increase hematology research.
项目概要/摘要-细胞采购和处理核心 Cell采购和处理(Cell P&P)核心的目的和目标仍然是促进 了解造血和非恶性疾病通过高质量的分布, 血液学研究界的造血产品。为了满足这一需求, Cell P&P Core于1999年在最初的CCEH P30下成立。在近20年的历史中, Cell P&P Core已被公认为正常造血细胞产品的国家资源, 69家机构的171名研究人员证明, 前一个奖项。此外,对核心方案资源的利用继续增加, 这些研究促进了我们对控制正常造血的生物学的理解, 非恶性疾病作为拟议奖励的一部分,细胞P&P核心将利用其专业知识, 基础设施和经验,以增加生产和利用高质量的产品,以推进 血液学研究领域,同时保持当前产品质量的高标准,如 研究战略。因此,Cell P&P Core提出以下建议: 具体目标1。扩大用户数量为最高的造血细胞富集产品 质量和一致性,以促进血液学研究。我们提出了三种新的方法来增加 用户号码。1)Cell P&P核心开发了一个新的用户满意度和需求计划, 反馈和识别新用户。2)核心将开发针对现有和新的虚拟研讨会 用户. 3)核心将开发一种新的资助机制,称为细胞P&P新研究者奖, 以大幅降低的价格提供资源。具体目标2。开发用户友好、综合和 造血标本综合数据管理系统(DMS)。拟议的DMS将 结合实时评估,以跟踪和检索捐助者特征、分析前变量 SOP、库存、质量控制、质量保证和样本分发,这将有两个主要的 有益效果。1)核心将能够更有效地为用户提供有关的基本变量, 他们的研究。2)核心将能够更迅速和全面地评估质量措施, 评价影响产品均匀性的潜在变量。具体目标3。开发新的创新 用户导向的产品,以促进血液学研究。鉴于新技术的爆炸式发展, 检查造血细胞,这仍然是一个挑战,研究人员获得的技能,利用 这些技术。通过将Cell P&P和Tool Cores的专业知识相结合,我们将能够高效地 开发和提供用户导向的产品给那些研究者,否则他们可能无法开发 这些产品在他们的实验室里。通过这些成果,我们将扩大这些领域的研究潜力, 研究人员,并提供了一个机制,以增加血液学研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DEREK L STIREWALT其他文献

DEREK L STIREWALT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DEREK L STIREWALT', 18)}}的其他基金

Novel Biomarkers to Risk-Stratify AML Patients with NPM1^Pos/FLT3-IT^Neg Genotype
对具有 NPM1^Pos/FLT3-IT^Neg 基因型的 AML 患者进行风险分层的新型生物标志物
  • 批准号:
    9899941
  • 财政年份:
    2016
  • 资助金额:
    $ 7.55万
  • 项目类别:
Novel Biomarkers to Risk-Stratify AML Patients with NPM1^Pos/FLT3-IT^Neg Genotype
对具有 NPM1^Pos/FLT3-IT^Neg 基因型的 AML 患者进行风险分层的新型生物标志物
  • 批准号:
    9105139
  • 财政年份:
    2016
  • 资助金额:
    $ 7.55万
  • 项目类别:
Novel Biomarkers to Risk-Stratify AML Patients with NPM1^Pos/FLT3-IT^Neg Genotype
对具有 NPM1^Pos/FLT3-IT^Neg 基因型的 AML 患者进行风险分层的新型生物标志物
  • 批准号:
    9452035
  • 财政年份:
    2016
  • 资助金额:
    $ 7.55万
  • 项目类别:
Stem Cell and Transplantation Biology
干细胞和移植生物学
  • 批准号:
    10472478
  • 财政年份:
    2015
  • 资助金额:
    $ 7.55万
  • 项目类别:
Cell Procurement & Processing
电池采购
  • 批准号:
    10207253
  • 财政年份:
    2015
  • 资助金额:
    $ 7.55万
  • 项目类别:
Stem Cell and Transplantation Biology
干细胞和移植生物学
  • 批准号:
    10675711
  • 财政年份:
    2015
  • 资助金额:
    $ 7.55万
  • 项目类别:
Cell Procurement & Processing
电池采购
  • 批准号:
    10675715
  • 财政年份:
    2015
  • 资助金额:
    $ 7.55万
  • 项目类别:
Cell Procurement & Processing
电池采购
  • 批准号:
    10472481
  • 财政年份:
    2015
  • 资助金额:
    $ 7.55万
  • 项目类别:
Discovery and Optimization of AML Prognostic Biomarkers
AML 预后生物标志物的发现和优化
  • 批准号:
    8625275
  • 财政年份:
    2012
  • 资助金额:
    $ 7.55万
  • 项目类别:
Discovery and Optimization of AML Prognostic Biomarkers
AML 预后生物标志物的发现和优化
  • 批准号:
    9024460
  • 财政年份:
    2012
  • 资助金额:
    $ 7.55万
  • 项目类别:

相似海外基金

Impact of preanalytic procurement and processing variables on the detection of HCC DNA in urine
分析前采购和处理变量对尿液中 HCC DNA 检测的影响
  • 批准号:
    10549981
  • 财政年份:
    2023
  • 资助金额:
    $ 7.55万
  • 项目类别:
Prostate Needle Biopsies: Impact of Preanalytical Procurement and Processing Variables on the Detection of Gene Expression Signatures of Prostate Cancer Aggressiveness
前列腺针活检:分析前采购和处理变量对前列腺癌侵袭性基因表达特征检测的影响
  • 批准号:
    10457135
  • 财政年份:
    2022
  • 资助金额:
    $ 7.55万
  • 项目类别:
Human Tissue Procurement and Processing Core
人体组织采购和加工核心
  • 批准号:
    10707550
  • 财政年份:
    2022
  • 资助金额:
    $ 7.55万
  • 项目类别:
Prostate Needle Biopsies: Impact of Preanalytical Procurement and Processing Variables on the Detection of Gene Expression Signatures of Prostate Cancer Aggressiveness
前列腺针活检:分析前采购和处理变量对前列腺癌侵袭性基因表达特征检测的影响
  • 批准号:
    10649631
  • 财政年份:
    2022
  • 资助金额:
    $ 7.55万
  • 项目类别:
Human Tissue Procurement and Processing Core
人体组织采购和加工核心
  • 批准号:
    10594338
  • 财政年份:
    2022
  • 资助金额:
    $ 7.55万
  • 项目类别:
Core B: Tissue Procurement and Processing
核心 B:组织采购和加工
  • 批准号:
    10593848
  • 财政年份:
    2022
  • 资助金额:
    $ 7.55万
  • 项目类别:
Core B: Tissue Procurement and Processing
核心 B:组织采购和加工
  • 批准号:
    10707425
  • 财政年份:
    2022
  • 资助金额:
    $ 7.55万
  • 项目类别:
Human Tissue Procurement and Processing Core
人体组织采购和加工核心
  • 批准号:
    10593660
  • 财政年份:
    2022
  • 资助金额:
    $ 7.55万
  • 项目类别:
Human Tissue Procurement and Processing Core
人体组织采购和加工核心
  • 批准号:
    10707433
  • 财政年份:
    2022
  • 资助金额:
    $ 7.55万
  • 项目类别:
Tissue Procurement and Processing Core
组织采购和加工核心
  • 批准号:
    10646151
  • 财政年份:
    2020
  • 资助金额:
    $ 7.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了